Men and women aged 18 years or more

with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization

with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization

Participants who are planned to undergo PCI will be the target participants

Elevated troponin I

creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)

ST segment depression >= 0.1 mV (>=1 mm)

transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads

Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.

Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.

Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)

known hypersensitivity to any component of the current investigational product;

Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment

History of a bleeding diathesis

evidence of active abnormal bleeding within 30 days before enrollment

History of a hemorrhagic stroke at any time

Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;

Major surgery within 2 weeks prior to enrollment

Known platelet count <100,000/mm^3

Uncontrolled cardiac arrhythmia;

Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;

Active or chronic hepatobiliary or hepatic disease

Anticipated staged PCI

Anticipated intracoronary brachytherapy

Concurrent or anticipated treatment with warfarin

Concurrent or anticipated treatment with factor Xa inhibitor after enrollment

Concurrent or anticipated treatment with direct thrombin inhibitor after enrollment

Concurrent or anticipated treatment with or antiplatelet agents after enrollment